Over-expression of the MDM2 gene is found in some cases of haematological malignancies.
We looked for MDM2 gene amplification and over-expression by Southern and Northern blot analysis in 135 and 66 cases of haematological malignancies, including ALL, AML, CML in chronic phase, CLL, MDS, PLL, non-Hodgkin's lymphoma (NHL) and myeloma. No amplification of the gene was found. An over-expression of MDM2 RNA was seen in 9/66 (14%) patients tested, including 3/9 ALL, 3/24 AML, 2/4 myelomas, 1/1 PLL, but 0/2 CML, 0/2 NHL and 0/21 MDS. None of the patients over-expressing MDM2 had modifications of P53 gene transcript or p53 mutations. Most of the patients over-expressing MDM2 gene had poor prognostic features (including 'unfavourable' cytogenetic abnormalities), poor response to chemotherapy and short survival. Our findings suggest that over-expression of MDM2 is seen in a relatively small number of haematological malignancies, and is associated with poor prognosis.
Quesnel
B
B
Inserm U124, Institut de Recherches sur le Cancer de Lille, France.
Preudhomme
C
C
Oscier
D
D
Lepelley
P
P
Collyn-d'Hooghe
M
M
Facon
T
T
Zandecki
M
M
Fenaux
P
P
D000368:Aged; D000369:Aged, 80 and over; D015152:Blotting, Northern; D015139:Blotting, Southern; D005784:Gene Amplification; D015870:Gene Expression; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics; D009101:Multiple Myeloma / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000235:genetics; D009687:Nuclear Proteins; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D051736:Proto-Oncogene Proteins c-mdm2
D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2